Akaeso Pharmaceuticals | Drug Development

Bridging Research to Inflexion Point
Empowering Drug Development for Breakthrough Therapies

Akaeso Pharmaceuticals is a Belgian drug development company specializing in advancing innovative therapies for rare and incurable diseases. We collaborate with research institutions and companies, transforming promising drug candidates into market-ready solutions, ready for licensing and commercialization by leading pharmaceutical partners worldwide.

more soon

Drug Development

Akaeso Pharmaceuticals excels in translating scientific discoveries into viable therapeutics. With a dedicated team and strategic partnerships, we navigate the complex drug development process, optimizing efficacy, safety, and commercial potential for breakthrough medicines.

Transforming Innovation

Akaeso Pharmaceuticals specializes in addressing unmet medical needs in rare and incurable diseases, with a key focus on fibrosis. Our mission is to develop novel solutions that bring hope to patients and improve their quality of life..

Experienced Team

Akaeso is led and supported by a diverse team with complementary expertise from the medical sciences with long academic and industrial research experience as well as from the pharmaceutical industry and the capital markets.

The Pressing Unmet Healthcare Challenge

Affecting a substantial number of individuals worldwide*, fibrotic diseases are marked by chronic tissue scarring and dysfunction. These conditions give rise to diverse clinical manifestations often linked to organ impairment and reduced quality of life.

.

700

million people have Chronic Kidney Disease

100

thousand people have Cystic Fibrosis

15

per 100,000 have Idiopathic Pulmonary Fibrosis

84

$ billion cost in the US for Chronic Kidney Disease

We are here to make a difference

Experience the Future of Pharmaceutical Innovation with Akaeso Pharmaceuticals

Novel Drug Development Model

Strategic collaborations, licensing novel drugs, and advancing therapeutics for corporate deals—our innovative drug development model.

Efficient Global Commercialization

Strategically commercializing with protected IP, global partnerships, and cost-efficiency for leveraging global sales capabilities.

Pharma Trends: Growth Opportunities

Rising healthcare spending, growing chronic diseases, and acquisition prospects fuel opportunities for novel products in pharma industry.

Investing in Transformative Solutions

Untapped potential lies within the realm of fibrotic diseases, presenting a unique investment opportunity to address unmet medical needs and revolutionize patient outcomes worldwide

Liver Fibrosis

Liver fibrosis is a progressive scarring of the liver tissue, often caused by chronic liver diseases such as hepatitis or alcohol abuse.

Kidney fibrosis

Kidney fibrosis refers to the excessive formation of scar tissue in the kidneys, leading to impaired kidney function and potential organ failure.

Amyotrophic Lateral Sclerosis or Motor Neuron Disease

Idiopathic Pulmonary Fibrosis

IPF is a chronic lung disease characterized by the progressive scarring of lung tissue, resulting in difficulty breathing and reduced lung function.

Cystic fibrosis

Cystic fibrosis is a genetic disorder affecting multiple organs, primarily the lungs and digestive system, causing thick mucus production and impaired organ function.

Myocardial Fibrosis

Myocardial fibrosis involves the buildup of excessive scar tissue in the heart, leading to impaired cardiac function and potentially heart failure.

Scleroderma

Scleroderma is a connective tissue disorder characterized by excessive collagen production, leading to skin thickening, organ damage, and various systemic symptoms.

Inter-disciplinary capabilities

Akaeso Pharmaceuticals is committed to pushing the boundaries of innovation by fostering multidisciplinary research collaborations. We actively engage with leading companies, universities, and research institutions to leverage diverse expertise, capitalize on collaboration opportunities, and drive advancements in drug development. Additionally, our strategic partnerships enable us to access specialized resources and capabilities through Contract Research Organizations (CROs), ensuring efficient and effective progress in our drug development programs.

Learn more

Ignite the Sparks of Innovation

Our Ingenious Approach

A Strategic Alliance Awaits Companies and Research Institutions, Entrusting their Pioneering Discoveries to Our Expertise. As Visionary Collaborators, We Nurture and Develop Ideas, Securing Funding, Reaching Inflection Points, and Sealing Transformative Deals with Pharma Partners for Global Commercialization Success. Together, We Unleash the Full Potential of Brilliant Minds.